04 October 2023
04 October 2023
The technology-led partnership will optimise and improve clinical trial conduct to benefit patients, sites and sponsors.
The Phase II study met its primary endpoint with 80% of infants with SMA sitting without support for at least five seconds after 1 year with Evrysdi.
OncoHost’s PROphet platform will build patient selection and outcome profiles in the Phase III trial of serplulimab for small-cell lung cancer.
So far, the company has raised $29m in funding to develop its intelligence technology for various purposes.
Initial monotherapy efficacy data is expected for the Phase I/II study in Q4 2023.
A drug developed for the treatment of advanced HER2-positive gastric cancer has reported an overall response rate of 52% as part of an international study.
The project will expand on Ubiquigent’s DUB-based drug discovery platform and recent developments in activity-based probes.
In the Phase I/II study, healthy volunteers received two administrations one week apart, and MDD participants received administrations three weeks apart.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
